Correlation between chromosome 9p21 locus deletion and prognosis in clinically localized prostate cancer

Imagem de Miniatura
Arquivos
art_BARROS_Correlation_between_chromosome_9p21_locus_deletion_and_prognosis_2017.PDF (241.13 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WICHTIG PUBLISHING
Autores
BARROS, Erika Aparecida Felix de
LIMA, Amanda Eunice Ramos
SALGUEIRO, Jose Lucas
FONTES, Douglas
DELLE, Humberto
Citação
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, v.32, n.2, p.E248-E254, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Some studies have reported that deletions at chromosome arm 9p occur frequently and represent a critical step in carcinogenesis of some neoplasms. Our aim was to evaluate the deletion of locus 9p21 and chromosomes 3, 7 and 17 in localized prostate cancer (PC) and correlate these alterations with prognostic factors and biochemical recurrence after surgery. Methods: We retrospectively evaluated surgical specimens from 111 patients with localized PC who underwent radical prostatectomy. Biochemical recurrence was defined as a prostate-specific antigen (PSA) >0.2 ng/mL and the mean postoperative follow-up was 123 months. The deletions were evaluated using fluorescence in situ hybridization with centromeric and locus-specific probes in a tissue microarray containing 2 samples from each patient. We correlated the occurrence of any deletion with pathological stage, Gleason score, ISUP grade group, PSA and biochemical recurrence. Results: We observed a loss of any probe in only 8 patients (7.2%). The most common deletion was the loss of locus 9p21, which occurred in 6.4% of cases. Deletions of chromosomes 3, 7 and 17 were observed in 2.3%, 1.2% and 1.8% patients, respectively. There was no correlation between chromosome loss and Gleason score, ISUP, PSA or stage. Biochemical recurrence occurred in 83% cases involving 9p21 deletions. Loss of 9p21 locus was significantly associated with time to recurrence (p = 0.038). Conclusions: We found low rates of deletion in chromosomes 3, 7 and 17 and 9p21 locus. We observed that 9p21 locus deletion was associated with worse prognosis in localized PC treated by radical prostatectomy.
Palavras-chave
FISH, 9p21 locus, Prognosis, Prostate cancer
URI
https://observatorio.fm.usp.br/handle/OPI/19880
Referências
  1. Bettin A, 2016, INT J BIOL MARKER, V31, pE153, DOI 10.5301/jbm.5000184
  2. Boyd LK, 2012, GENE CHROMOSOME CANC, V51, P579, DOI 10.1002/gcc.21944
  3. Chang LL, 2003, J UROLOGY, V170, P595, DOI 10.1097/01.ju.0000067626.37837.3e
  4. Cheng I, 2012, GENE CHROMOSOME CANC, V51, P66, DOI 10.1002/gcc.20932
  5. Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751
  6. CordonCardo C, 1997, CANCER RES, V57, P1217
  7. D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969
  8. de Oliveira D, 2014, UROL ONCOL-SEMIN ORI, V32, P601, DOI 10.1016/j.urolonc.2013.12.008
  9. Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780
  10. Eifler JB, 2013, BJU INT, V111, P22, DOI 10.1111/j.1464-410X.2012.11324.x
  11. Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530
  12. Grady B, 2001, J UROLOGY, V166, P1088, DOI 10.1016/S0022-5347(05)65927-7
  13. Heidenreich B, 2000, EUR UROL, V38, P475, DOI 10.1159/000020327
  14. JOOS S, 1995, GENE CHROMOSOME CANC, V14, P267, DOI 10.1002/gcc.2870140405
  15. Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690
  16. Mohler JL, 2016, J NATL COMPR CANC NE, V14, P19
  17. Moschini M, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0613-7
  18. Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.0.CO;2-Q
  19. OLOPADE OI, 1995, P NATL ACAD SCI USA, V92, P6489, DOI 10.1073/pnas.92.14.6489
  20. Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2
  21. Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x
  22. Pontes J, 2013, INT BRAZ J UROL, V39, P335, DOI 10.1590/S1677-5538.IBJU.2013.03.06
  23. Potters L, 2004, RADIOTHER ONCOL, V71, P29, DOI 10.1016/j.radonc.2003.12.011
  24. Reid-Nicholson MD, 2011, ANN DIAGN PATHOL, V15, P37, DOI 10.1016/j.anndiagpath.2010.07.011
  25. Reynolds MA, 2008, CANCER LETT, V271, P13, DOI 10.1016/j.canlet.2008.04.047
  26. Schroder FH, 2014, LANCET, V384, P2027, DOI 10.1016/S0140-6736(14)60525-0
  27. Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
  28. Spans L, 2013, INT J MOL SCI, V14, P10822, DOI 10.3390/ijms140610822
  29. Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
  30. VISAKORPI T, 1995, CANCER RES, V55, P342
  31. Zaytoun OM, 2011, UROLOGY, V78, P392, DOI 10.1016/j.urology.2011.04.042

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03